Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection

About this update from Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chengdu Easton Biopharmaceuticals Co., Ltd. Class A